Pulmonary Artery Pressure Trajectories in Heart Failure Patients Treated with GLP-1 Receptor Agonists
ESC Heart Failure · 2025
DOI: 10.1002/ehf2.15308 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Haoran Jiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Heart Failure, Glucagon-Like Peptide-1 Receptor Agonists, Glucagon-Like Peptides, Pulmonary Artery. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Aims
Data support favourable haemodynamic benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on improving cardiac structural abnormalities and function in patients with heart failure (HF). However, the direct haemodynamic effects of GLP-1 RAs remain inadequately characterized. We aim to investigate temporal trends of pulmonary artery pressure (PAP) in HF patients receiving GLP-1 RAs. Methods and results In this single-centre retrospective cohort study, we identified HF patients with a CardioMEMS device who received semaglutide or tirzepatide for at least 6 months during the monitoring period. Patients who were already on GLP-1 RAs prior to device implantation were excluded. The relationship between weight change and PAPs was assessed using Pearson correlation. A total of nine patients were included (54 years, BMI 41.4 kg/m2, 67% men, 44% with EF < 40%, 89% diabetes, 89% semaglutide). Median dose of semaglutide (or equivalent) at 6 months was 0.9 (range 0.25–1) mg/week. Body weight significantly decreased from 123.6 to 117.2 kg (P = 0.047), while guideline-directed medical therapy (GDMT) and loop diuretic uses and dosages remained unchanged. Significant reductions were observed in systolic PAP (38.9 to 34.0 mmHg, P = 0.045), diastolic PAP (20.0 to 17.8 mmHg, P = 0.019) and mean PAP (27.3 to 24.3 mmHg, P = 0.018). There was a significant correlation between weight loss and reductions in systolic PAP (r = 0.69, P = 0.04) and mean PAP (r = 0.72, P = 0.029).
Conclusions
GLP1-RA use in HF patients was significantly associated with reductions in body weight and PAPs at 6 months, despite no changes in GDMT and loop diuretic doses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA.
- Department of Medicine, Jefferson Einstein Hospital, Philadelphia, Pennsylvania, USA.
- Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
- Duke Clinical Research Institute, Durham, North Carolina, USA.
- Department of Pharmacy, Duke University Hospital, Durham, North Carolina, USA.
ORCID-Profile: Phuuwadith Wattanachayakul
Zitieren
APA
Jiang, H., Wattanachayakul, P., Kittipibul, V., Nicolsen, E., McVeigh, T., Kamneva, O., & Fudim, M. (2025). Pulmonary Artery Pressure Trajectories in Heart Failure Patients Treated with GLP-1 Receptor Agonists. ESC Heart Failure. https://doi.org/10.1002/ehf2.15308
Vancouver
Jiang H, Wattanachayakul P, Kittipibul V, Nicolsen E, McVeigh T, Kamneva O, et al. Pulmonary Artery Pressure Trajectories in Heart Failure Patients Treated with GLP-1 Receptor Agonists. ESC Heart Failure. 2025. doi:10.1002/ehf2.15308
BibTeX
@article{Jiang2025,
author = {Jiang, Haoran and Wattanachayakul, Phuuwadith and Kittipibul, Veraprapas and Nicolsen, Erika and McVeigh, Todd and Kamneva, Oksana and Fudim, Marat},
title = {Pulmonary Artery Pressure Trajectories in Heart Failure Patients Treated with GLP-1 Receptor Agonists},
journal = {ESC Heart Failure},
year = {2025},
doi = {10.1002/ehf2.15308}
}
EUVIMED